Kāohi a hoʻopaʻa i ka maʻi kanesa!

ʻO kēlā me kēia makahiki ma ʻApelila 17th ka World Cancer Day.

01 Hōʻikeʻike ʻia o ka maʻi maʻi maʻi honua

I nā makahiki i hala iho nei, me ka piʻi mau ʻana o ke ola o ka poʻe a me ke kaumaha o ka noʻonoʻo, ke piʻi aʻe nei ka nui o nā maʻi maʻi i kēlā me kēia makahiki.

ʻO nā maʻi maʻi ʻino (maʻi maʻi) ua lilo i hoʻokahi o nā pilikia olakino lehulehu e hoʻoweliweli koʻikoʻi i ke olakino o ka heluna Kina.Wahi a nā ʻikepili helu hou loa, ʻo ka make ʻana o nā maʻi ʻaʻai maʻi maʻi he 23.91% o nā kumu a pau o ka make ma waena o nā kamaʻāina, a ke piʻi mau nei ka piʻi ʻana a me ka make ʻana o nā maʻi maʻi maʻi i nā makahiki he ʻumi i hala.Akā ʻaʻole ʻo ka maʻi maʻi he "hoʻopaʻi make."Ua kuhikuhi maopopo ka World Health Organization i ka wā e ʻike mua ʻia ai, hiki i ka 60% -90% o nā maʻi maʻi ke ho'ōla ʻia!Hiki ke pale ʻia ka hapakolu o nā maʻi kanesa, hiki ke hoʻōla ʻia ka hapakolu o nā maʻi maʻi, a hiki ke mālama ʻia ka hapakolu o nā maʻi maʻi e hoʻolōʻihi i ke ola.

02 He aha ke koko

Hōʻike ʻo Tumor i ke kino hou i hana ʻia e ka hoʻonui ʻia ʻana o nā ʻiʻo ʻiʻo kūloko ma lalo o ka hana o nā ʻano tumorigenic like ʻole.Ua ʻike ʻia nā haʻawina e loaʻa ana nā hoʻololi ʻokoʻa i nā cell tumor mai nā cell maʻamau.I ka manawa like, hiki ke hoʻololi i nā cell tumor i nā loli i ke kaiapuni metabolic ma o ka hoʻololi ʻana ma waena o ka glycolysis a me ka phosphorylation oxidative.

03 ʻO ka maʻi maʻi maʻi maʻi hoʻokahi

Hoʻokumu ʻia ka mālama ʻana i ka maʻi maʻi kanaka ma luna o ka ʻike hōʻoia o nā genes i loaʻa i ka maʻi a me nā hopena o ka noiʻi lapaʻau e pili ana i nā hōʻike.Hāʻawi ia i ke kumu no nā mea maʻi e loaʻa ai ka hoʻolālā lapaʻau kūpono, i lilo i ke ʻano o ka hoʻomohala olakino hou.Ua hōʻoia nā haʻawina lāʻau lapaʻau ma ka ʻike ʻana i ka mutation gene o nā biomarkers, gene SNP type, gene a me kona kūlana hōʻike protein i nā laʻana olaola o nā maʻi maʻi maʻi e wānana i ka pono o ka lāʻau lapaʻau a loiloi i ka prognosis, a alakaʻi i ka lāʻau lapaʻau pilikino, hiki iā ia ke hoʻomaikaʻi i ka maikaʻi a hōʻemi i nā pōʻino. reactions , e paipai i ka hoʻohana pono ʻana i nā kumuwaiwai olakino.

Hiki ke hoʻokaʻawale ʻia ka hoʻāʻo molecular no ka maʻi kanesa i 3 mau ʻano nui: diagnostic, hereditary, a me therapeutic.ʻO ka hoʻāʻo Therapeutic ma ke kumu o ka mea i kapa ʻia ʻo "therapeutic pathology" a i ʻole ka lāʻau lapaʻau pilikino, a ʻoi aku ka nui o nā antibodies a me nā mea hoʻopaneʻe mole liʻiliʻi e hiki ke hoʻopaʻa ʻia i nā ʻano kī nui a me nā ala hōʻailona hiki ke hoʻohana ʻia i ka mālama ʻana i nā ʻōpū.

ʻO ka molecular targeted therapy of tumors targets the marker molecules of tumor cells and intervenes in the process of cancerous cells.Loaʻa kona hopena ma nā pūnaewele tumora, akā he liʻiliʻi ka hopena ma nā pūnaewele maʻamau.Hiki ke hoʻohana ʻia nā mea e loaʻa ai nā mea hoʻoulu ʻana i ka tumor, nā molekele transduction hōʻailona, ​​​​nā protein cycle cell, nā mea hoʻoponopono apoptosis, nā enzyme proteolytic, vascular endothelial growth factor, a pēlā aku.Ma Dekemaba 28, 2020, ʻo ka "Administrative Measures for the Clinical Application of Antineoplastic Drugs (Trial)" i hoʻopuka ʻia e ka National Health and Medical Commission i hōʻike maopopo ʻia: No nā lāʻau lapaʻau me nā pahuhopu gene maopopo, pono e hahai ʻia ke kumu o ka hoʻohana ʻana iā lākou ma hope. ka hoʻāʻo ʻana i ke gene.

04 ʻO ka hoʻāʻo genetic i hoʻopaʻa ʻia i ka tumor

Nui nā ʻano hoʻololi genetic i loko o nā ʻōpū, a hoʻohana nā ʻano hoʻololi ʻokoʻa i nā lāʻau lapaʻau like ʻole.Ma ka wehewehe wale ʻana i ke ʻano o ka mutation gene a me ke koho pololei ʻana i ka lāʻau lapaʻau i manaʻo ʻia e hiki i nā maʻi ke pōmaikaʻi.Ua hoʻohana ʻia nā ʻano molecular detection no ka ʻike ʻana i ka ʻokoʻa o nā genes e pili ana i nā lāʻau lapaʻau maʻamau i hoʻopaʻa ʻia i loko o nā ʻōpū.Ma ka nānā ʻana i ka hopena o nā ʻano genetic i ka hopena o ka lāʻau lapaʻau, hiki iā mākou ke kōkua i nā kauka e hoʻomohala i ka hoʻolālā lapaʻau ponoʻī.

05 Hoʻoholo

Ua hoʻomohala ʻo Macro & Micro-Test i kahi ʻano o nā pahu ʻike no ka ʻike ʻana i nā ʻano maʻi tumora, e hāʻawi ana i kahi hopena holoʻokoʻa no ka lāʻau lapaʻau i hoʻopaʻa ʻia.

Kāne EGFR Gene 29 Mutations Detection Kit (Fluorescence PCR)

Hoʻohana ʻia kēia kit no ka ʻike in vitro qualitatively o nā mutation maʻamau i nā exons 18-21 o ka gene EGFR i nā laʻana mai nā maʻi maʻi maʻi maʻi maʻi ʻaʻole liʻiliʻi liʻiliʻi.

1. Hoʻokomo ka ʻōnaehana i ka mana o ka maikaʻi kuhikuhi kūloko, hiki ke nānā pono i ke kaʻina hana hoʻokolohua a hōʻoia i ka maikaʻi o ka hoʻokolohua.

2. Kiʻekiʻe sensitivity: ʻO ka ʻike ʻana o ka hopena nucleic acid reaction solution hiki ke ʻike paʻa i ka helu mutation o 1% ma lalo o ke kāʻei o 3ng/μL ʻano hihiu.

3. Kiʻekiʻe kikoʻī: ʻAʻohe cross-rection me ke ʻano hihiu o ke kanaka genomic DNA a me nā ʻano mutant ʻē aʻe.

 

KRAS 8 Mutations Detection Kit (Fluorescence PCR)

Kuhi ʻia kēia pahu no ka ʻike in vitro qualitative o 8 mau hoʻololi i nā codons 12 a me 13 o K-ras gene i loko o ka DNA i unuhi ʻia mai nā ʻāpana pathological i hoʻopili ʻia e ke kanaka.

1. Hoʻokomo ka ʻōnaehana i ka mana o ka maikaʻi kuhikuhi kūloko, hiki ke nānā pono i ke kaʻina hana hoʻokolohua a hōʻoia i ka maikaʻi o ka hoʻokolohua.

2. Kiʻekiʻe sensitivity: ʻO ka ʻike ʻana o ka hopena nucleic acid reaction solution hiki ke ʻike paʻa i ka helu mutation o 1% ma lalo o ke kāʻei o 3ng/μL ʻano hihiu.

3. Kiʻekiʻe kikoʻī: ʻAʻohe cross-rection me ke ʻano hihiu o ke kanaka genomic DNA a me nā ʻano mutant ʻē aʻe.

 

ʻO ke kanaka EML4-ALK Fusion Gene Mutation Detection Kit (Fluorescence PCR)

Hoʻohana ʻia kēia kit e ʻike pono i nā ʻano mutation 12 o EML4-ALK fusion gene i nā laʻana o nā mea maʻi maʻi maʻi maʻi maʻi ʻaʻai liʻiliʻi liʻiliʻi i vitro.

1. Hoʻokomo ka ʻōnaehana i ka mana o ka maikaʻi kuhikuhi kūloko, hiki ke nānā pono i ke kaʻina hana hoʻokolohua a hōʻoia i ka maikaʻi o ka hoʻokolohua.

2. ʻIke kiʻekiʻe: Hiki i kēia pahu ke ʻike i nā hoʻololi fusion ma lalo o 20 kope.

3. Kiʻekiʻe kikoʻī: ʻAʻohe cross-rection me ke ʻano hihiu o ke kanaka genomic DNA a me nā ʻano mutant ʻē aʻe.

 

ʻO ke kanaka ROS1 Fusion Gene Mutation Detection Kit (Fluorescence PCR)

Hoʻohana ʻia kēia pahu i ka ʻike in vitro qualitative o 14 ʻano o ROS1 fusion gene mutations i loko o nā laʻana maʻi maʻi maʻi ʻaʻai liʻiliʻi liʻiliʻi.

1. Hoʻokomo ka ʻōnaehana i ka mana o ka maikaʻi kuhikuhi kūloko, hiki ke nānā pono i ke kaʻina hana hoʻokolohua a hōʻoia i ka maikaʻi o ka hoʻokolohua.

2. ʻIke kiʻekiʻe: Hiki i kēia pahu ke ʻike i nā hoʻololi fusion ma lalo o 20 kope.

3. Kiʻekiʻe kikoʻī: ʻAʻohe cross-rection me ke ʻano hihiu o ke kanaka genomic DNA a me nā ʻano mutant ʻē aʻe.

 

ʻO ke kanaka BRAF Gene V600E Mutation Detection Kit (Fluorescence PCR)

Hoʻohana ʻia kēia pahu hoʻāʻo e ʻike pono i ka hoʻololi ʻana o ka BRAF gene V600E i loko o nā ʻano kikoo paraffin-embedded o ka melanoma kanaka, colorectal cancer, thyroid cancer and lung cancer in vitro.

1. Hoʻokomo ka ʻōnaehana i ka mana o ka maikaʻi kuhikuhi kūloko, hiki ke nānā pono i ke kaʻina hana hoʻokolohua a hōʻoia i ka maikaʻi o ka hoʻokolohua.

2. Kiʻekiʻe sensitivity: ʻO ka ʻike ʻana o ka hopena nucleic acid reaction solution hiki ke ʻike paʻa i ka helu mutation o 1% ma lalo o ke kāʻei o 3ng/μL ʻano hihiu.

3. Kiʻekiʻe kikoʻī: ʻAʻohe cross-rection me ke ʻano hihiu o ke kanaka genomic DNA a me nā ʻano mutant ʻē aʻe.

 

Helu Helu	inoa mea kūʻai	Hōʻike
HWTS-TM012A/B	ʻO ke kanaka EGFR Gene 29 Mutations Detection Kit (Fluorescence PCR)	16 ho'āʻo/kit，32 hōʻike/kit
HWTS-TM014A/B	KRAS 8 Mutations Detection Kit(Fluorescence PCR)	24 ho'āʻo/kit，48 hōʻike/kit
HWTS-TM006A/B	ʻO ke kanaka EML4-ALK Fusion Gene Mutation Detection Kit (Fluorescence PCR)	20 ho'āʻo/kit，50 hoʻāʻo/kit
HWTS-TM009A/B	ʻO ke kanaka ROS1 Fusion Gene Mutation Detection Kit (Fluorescence PCR)	20 ho'āʻo/kit，50 hoʻāʻo/kit
HWTS-TM007A/B	ʻO ke kanaka BRAF Gene V600E Mutation Detection Kit(Fluorescence PCR)	24 ho'āʻo/kit，48 hōʻike/kit
HWTS-GE010A	ʻO ke kanaka BCR-ABL Fusion Gene Mutation Detection Kit (Fluorescence PCR )	24 hōʻike / pahu